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ABSTRACT
Peptide insertions in codons 67–71 of the reverse transcriptase (RT) pol gene were detected in 11 (2.7%)
of 414 genotypic analyses performed in a hospital cohort of 2900 outpatients with human immuno-
deﬁciency virus type 1 (HIV-1) infection. The duration of antiretroviral treatment (bi- or tri-therapy)
before the detection of insertions ranged from 12 to 60 months. Dipeptide insertions were detected in
ten patients, of which the most frequent was serine–serine. A monopeptide insertion was diagnosed
once. The amino-acid composition patterns of insertions varied with time in ﬁve of the 11 patients.
Peptide insertions were always associated with various patterns of pre-existing or appearing resistance
mutations in the RT pol gene to different antiretroviral drugs. Genotypic-guided treatment resulted in
virological and immunological improvement in two patients. In contrast, the remaining patients did not
respond to any of the various antiretroviral regimens prescribed. Furthermore, various patterns of
resistance mutations developed to the prescribed antiretroviral drugs, with AIDS-related conditions
leading to death in two patients. It was concluded that peptide insertion in this region of the HIV-1 RT
pol gene constitutes a rare cause of persistent therapeutic failure, and that management of such patients
remains challenging despite successive genotypic analyses aimed at detecting mutations conferring
antiretroviral drug resistance.
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INTRODUCTION
Selection of drug-resistant human immunodeﬁ-
ciency virus type 1 (HIV-1) mutant variants is a
major cause of antiretroviral treatment failure.
Resistance to HIV reverse transcriptase (RT)
inhibitors usually results from base-pair muta-
tions leading to amino-acid substitutions in the
RT pol gene. The substitution mutation Q151M,
or insert-deletion mutations conferring multi-
drug resistance (MDR), may occur in a minority
of cases [1–7]. MDR-related insertions generally
consist of two amino-acids inserted following
codon 69 of the RT pol gene, most frequently
serine–serine (S–S) and serine–glycine (S–G), and
these are associated with high phenotypic resist-
ance to various nucleoside RT inhibitor (NRTI)
analogues [6]. Management of patients carrying
MDR variants remains challenging [2–4,7], but
the outcome of peptide insertions has, until now,
been poorly documented. Previously reported
follow-ups of patients carrying variants with
peptide rearrangements in the pol gene have
been limited to < 1 year [6,7]. The present study
analysed the clinical, virological and immunolo-
gical outcome of a cohort of 11 patients carrying
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HIV-1 variants showing rearrangements in co-
dons 67–71 of the RT pol gene region over a
period of 2–6 years.
PATIENTS AND METHODS
Study population and sample processing
The Service des Maladies Infectieuses et Tropicales at Rots-
child Hospital, Paris, follows a cohort of 2900 HIV-infected
outpatients. Between February 1996 and June 1999, routine
genotypic analyses for drug-resistance mutations were per-
formed for 414 patients. Eleven (2.7%) patients whose HIV-1
variants showed peptide rearrangements in the RT pol gene
were included in a prospective follow-up. Plasma was separ-
ated from EDTA-anticoagulated blood and stored in aliquots
at ) 80 C until used for further analyses.
Virological and immunological surrogate
markers
HIV-1 RNA in plasma was quantiﬁed by branched-chain DNA
signal ampliﬁcation. During the study period, three genera-
tions of assays were used successively (Quantiplex HIV-RNA
v.1.0, v.2.0 and v.3.0; Chiron Diagnostics, Emeryville, CA,
USA), with detection limits of 10 000, 500 and 50 copies ⁄mL,
respectively. Absolute numbers of CD4 T-lymphocytes were
determined in whole blood by ﬂow cytometry with a FACScan
cytoﬂuorometer and Cellquest software (Becton Dickinson,
Mountain View, CA, USA). CD4 T-cell counts and plasma HIV
RNA levels were measured at baseline, and periodically
thereafter. Virological or immunological failures following
therapy were deﬁned as a viral load of > 30 000 copies ⁄mL, or
as an absolute number of CD4 T cells of < 200 ⁄ lL, respectively,
after antiretroviral therapy for 6 months. A signiﬁcant varia-
tion in plasma viral load or in CD4 T-cell count was deﬁned as
a variation of at least 0.5 log copies ⁄mL, or 50 · 106 cells ⁄L,
between two determinations separated by at least 6 months.
Sequencing of reverse transcriptase and
protease
Reverse transcriptase and protease gene sequences were
obtained from plasma cell-free HIV-1 RNA, as described
previously [6,8], but with slight modiﬁcations in the primer
sets used. In brief, HIV-1 virions in 1 mL of plasma were
pelleted by centrifugation at 30 000 g for 60 min. The pellets
were resuspended in 140 lL of RNAse-free sterile distilled
water, and RNA was recovered by selective binding to a
silica-based membrane in a spin column (High Pure RNA
Isolation Kit; Boehringer, Mannheim, Germany). RNA was
reverse-transcribed to cDNA, and the protease p32 pol gene
was ampliﬁed by nested PCR with sets of speciﬁc primers.
Two RT gene fragments (RT1: codons 6–152; RT2: codons
157–252) were ampliﬁed with the previously published
forward internal primers A and B [9], and the reverse
internal primers 5¢-GGTGATCCTTTCCATCC-3¢ for RT1 and
5¢-TCATTGGACAGTCCAGCT-3¢ for RT2. The protease gene
was ampliﬁed by nested PCR with forward and reverse
external primers 5¢-ATAATCCACCTATCCCAGTAGGAGG-
AAAT-3¢ and 5¢-GGTGATCCTTTCCATCC-3¢, respectively;
the forward and reverse internal primers were 5¢-AGA-
AGAGAGCTCCCAGGTTTGG-3¢ and 5¢-AGTCTCAATAGG
ACTAATGGG-3¢, respectively. The ﬁnal PCR products were
puriﬁed, followed by direct sequencing of amplicons with an
automated sequencer. Two opposing strands from each PCR
product were sequenced using the 5¢ and 3¢ inner primers
and aligned with Sequencer Navigator v.1.0.1 software
(Applied Biosystems, Warrington, UK). The sequences were
proof-read manually and aligned with the 1997–98 HIV-1
subtype B consensus sequence from the Los Alamos HIV
sequence database for comparison. Primary and secondary
mutations known to be associated with antiretroviral resist-
ance were recorded [10]. Other mutations, considered nat-
ural polymorphisms of the protease gene [11] or which have
not been previously described, were not recorded.
HIV-1 subtyping
HIV-1 subtypes were assessed by the BLAST program
(http://www.ncbi.nlm.nih.gov). Sequences yielding ambigu-
ous results were further compared to reference sequences by
phylogenetic analysis using the parsimony method [12].
RESULTS
Study population
Eleven (2.7%) of 414 patients for whom a resist-
ance genotype was determined showed peptide
rearrangements in the RT pol gene, and were
included in the prospective follow-up. Details of
virus subtypes, surrogate markers, duration of
follow-up, resistance mutation proﬁles, and pep-
tide rearrangements in the RT pol gene are given
in Table 1. All but one of the HIV-1 variants were
of the B subtype. The estimated duration of anti-
retroviral treatment before the appearance of
insertions ranged from 12 months (patients 1
and 9) to 60 months (patient 11), with a median
of 36 months (Fig. 1). Most patients were pre-
scribed various bi- and tri-combination therapies
at the time of peptide insertion occurrence (Fig. 1).
Patient 11 had taken zidovudine (ZDV) mono-
therapy for > 5 years, followed by zalcitabine
monotherapy (Fig. 1).
Molecular analysis and temporal evolution of
peptide insertions
In patient 11, the peptide rearrangement consisted
of a single tyrosine, coded by TAC, inserted
between codons 67 and 68 of the RT pol gene, in
association with the D67G, T69D and K70R
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mutations (Table 1). This insertion, and the asso-
ciated ﬂanking resistance mutations, appeared to
be stable during the follow-up.
In the ten other patients (1–10), the peptide
rearrangements consisted of double amino-acid
insertions between codons 68 and 69 of the RT pol
gene (Table 1). Pre-insertion RT pol gene
sequences obtained in patients 4–7 and 10 showed
the wild-type sequence (DSTKW) for codons
67–71 before the appearance of the insertion,
while they showed the mutations T69A, D67N
and K70R, respectively, in patients 2, 3 and 9. The
dipeptide insertion between codons 68 and 69 of
the RT pol gene consisted of alanine–serine (A–S)
in patient 6, of S–S in patients 1, 3, 5 and 9, and of
serine–glutamine (S–Q) in patient 7. In these ﬁve
latter patients, the temporal evolution of the
double amino-acid insertions showed stable rear-
rangements during the course of follow-up
(Table 1). In the four remaining patients (2, 4, 8
and 10), the dipeptide insertion evolved with
time. In patients 4 and 10, the A–S insertion
evolved into an alanine–valine (A–V) insertion. In
patient 2, the S–S insertion evolved into an A–S
insertion. Finally, in patient 8, the S-S insertion
evolved into a serine–cysteine (S–C) insertion. In
total, 14 different dipeptide insertions were iden-
tiﬁed in the successively analysed RT pol gene
sequences, namely six of S–S, four of A–S, two of
A–V, one of S–C, and one of S–Q. The ﬁrst amino-
acid of the dipeptide insertions was a serine in
eight sequences, and an alanine in six sequences.
The serine was coded for by different nucleotide
triplets, namely TCC (ﬁve times), TCT (two), and
AGC (one), while the alanine was always coded
for by the GCT triplet. The second amino-acid of
the dipeptide insertions was, in decreasing fre-
quency, a serine (ten sequences, coded by the
AGT triplet), a valine (two sequences, coded by
GTT), a glutamine and a cysteine.
The sequences between codons 67–71 ﬂanking
the dipeptide rearrangements may be described
as follows. The minor ZDV-resistance D67N and
K70R mutations disappeared when the dipeptide
insertion was identiﬁed for the ﬁrst time. In
patients 1, 2, 5 and 9, a D67E mutation was
noticed post-insertion. In patient 3, codon 67 was
originally an asparagine (N), which mutated to a
glutamate (E) at the time of the insertion. A
mutation of codon 68 (S68G) was only observed in
patient 10. The wild-type amino-acid T69 was
mutated in nine of ten patients. In patients 4, 6
and 8, the mutation in codon 69 was T69A. In
patients 3 and 7, the mutation was T69S, while in
patient 10, it was T69G. In patient 5, codon 69 ﬁrst
mutated to serine, and subsequently to glycine,
while in patient 9, a ﬁrst mutation in codon 69 to
alanine was followed by a change to glycine. In
patient 2, codon 69 was an alanine before the
insertion, which mutated to glycine and then
to serine post-insertion. Finally, codons 70 and
71 were wild-type (KW) after selection of the
dipeptide insertion in all patients.
The viability of the HIV-1 strains containing the
amino-acid insertions in the RT pol gene was
checked by cell culture of blood mononuclear
cells from four patients (1, 3, 9 and 10). The RT pol
gene sequences of HIV variants isolated from the
culture supernatants were identical to those
obtained from the plasma samples.
Associated resistance genotype
Various patterns of resistance mutations were
found consistently in patients whose HIV variants
developed peptide insertions. Before amino-acid
insertions, resistance mutation proﬁles were
determined for eight patients. All these patients
had received ZDV and had HIV variants showing
mutations associated with ZDV resistance; in
particular, the major resistance mutation T215Y
was found in all cases. Minor ZDV resistance
mutations comprised M41L (n ¼ 5), L210W
(n ¼ 5), D67N (n ¼ 1) and K70R (n ¼ 1). Interest-
ingly, the mutated codons 67N (patient 3) and 70R
(patient 9) reverted to 67E and wild-type 70K
codons, respectively, at the time of insertion.
Before peptide insertion, lamivudine (3TC)-trea-
ted patients 2 and 7 had the major 3TC-resistance
mutation M184V, which then disappeared when
3TC treatment was stopped.
At the time of detection of peptide insertions,
all patients had HIV variants harbouring the
major ZDV resistance mutation T215Y ⁄ F, fre-
quently associated with the minor resistance
mutations M41L and L210W. 3TC-treated patients
(1, 6 and 10) developed the M184V mutation at a
time close to that of insertion appearance.
After detection of peptide insertions, the
M184V ⁄ I mutation appeared in patients 3 and 5,
while it disappeared in patient 10 even though 3TC
treatment was continued. The major didanosine
(ddI) resistance mutation, L74V, appeared post-
insertion inpatient 1,whohad thenbeen takingddI
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for 11 months. The major stavudine (d4T) resist-
ance mutation V75M ⁄A appeared in patients
5 (V75M) and 9 (V75A) after 6 and 19 months,
respectively, of post-insertion d4T treatment.
Response to treatment and clinical-biological
outcome
The successive types of therapeutic associations of
antiretroviral drugs are depicted in Fig. 1 and
listed in detail in Table 1. The variations in CD4
T-cell count and HIV-1 RNA load in plasma are
shown for each patient in Fig. 2.
Before an insertion was diagnosed, all patients
were in therapeutic failure as deﬁned by both
virological (viral load of > 30 000 copies ⁄mL) and
immunological (CD4 count of < 200 ⁄lL) criteria,
except for patient 9 whose CD4 T-cell count
ranged from 200 to 350 ⁄ lL, and whose circulating
viral load was 14 120 copies ⁄mL at the time of
detection of insertions (Fig. 2).
Two patients (6 and 9) showed a favourable
immunological, virological and clinical evolution
following triple antiretroviral treatment commen-
ced after peptide rearrangement discovery. Patient
6 was in treatment failure when the insertion was
discovered, with a viral load of > 500 000 cop-
ies ⁄mL and a CD4 T-cell count of 12 ⁄ lL. After
starting antiprotease treatment (indinavir, 4
months; indinavir plus d4T, 13 months; indinavir
plus d4T plus 3TC, 19 months), the viral load
dropped below detectable limits (< 50 copies ⁄mL)
and the CD4 T-cell count increased from 12 ⁄lL to
400 ⁄ lL within 3 years. At discovery of the dipep-
tide insertion, patient 9 had a viral load of 40 000
copies ⁄mL and a CD4 T-cell count of 290 ⁄lL. With
triple therapy (indinavir plus twoNRTIs, 3 months
– the indinavir was stopped because of side-effects
to this drug; nelﬁnavir plus twoNRTIs, 12 months;
efavirenz plus twoNRTIs, 7 months), the viral load
dropped to < 50 copies ⁄mL and the CD4 T-cell
count increased from 290 ⁄lL to 600 ⁄ lL within
2 years.
In contrast, the other nine patients showed
therapeutic failure. Nine patients (1–5, 7, 8, 10 and
11) received NRTI treatment in combination with
indinavir after the insertions were discovered.
These patients were then treated unsuccessfully
with various antiretroviral combinations compri-
sing ritonavir plus saquinavir, or nelﬁnavir, or
one of the non-nucleoside RT inhibitors (NNRTIs)
nevirapine or efavirenz. Major protease inhibitor
resistance mutations (M46I, G48V, V82A ⁄T, T84V
and L90M) accumulated in most patients during
the course of follow-up. Six patients (1, 3, 4, 5, 7
and 8) selected HIV variants with major resistance
Fig. 1. Schematic representation of treatment history and codons 67–71 of the RT pol gene for 11 patients whose HIV-1
variants had peptide rearrangements. Black circles depict nucleoside reverse transcriptase inhibitor; black triangles depict
non-nucleoside reverse transcriptase inhibitor; black squares depict protease inhibitor. Antiretroviral drug regimens are
shown in detail in Table 1. Vertical lines indicate therapeutic shift. Open circles indicate strains without insertions. Grey
circles indicate insertion-containing strains. Triangles, diamonds and squares in grey indicate genetic evolution in codons
67–71. Open arrows indicate time of ﬁrst diagnosis of insertion rearrangement.
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mutations to NNRTIs: L100I (1 ⁄ 6), K101E (1 ⁄ 6),
K103N (3 ⁄ 6), Y181C (2 ⁄ 6) and G190A (4 ⁄ 6). No
signiﬁcant increase (> 0.5 log) in plasma HIV-1
RNA load or decrease in the CD4 T-cell count was
observed in these patients post-insertion. In
patients 1–5 and 10, the triple antiretroviral
therapy was not associated with a signiﬁcant
decrease (> 0.5 log in two successive samples). In
patients 7, 8 and 11, a transitory decrease in
circulating HIV-1 RNA load occurred for
15 months, 14 months and 6 months, respectively.
During the follow-up period, patient 9
remained stable, without virological or immuno-
logical failure. Patient 6 showed favourable
virological and immunological responses. All
remaining patients remained in virological and
immunological failure; all were suffering from at
least one disease indicative of AIDS during the
follow-up period. Patients 5 and 10 died 40 and
27 months, respectively, after the discovery of
peptide insertions.
DISCUSSION
In the present study, mono or dipeptide inser-
tions in the ﬁngers subdomain of the HIV-1 RT
pol gene constituted a rare and unstable event,
occurring in the context of antiretroviral thera-
peutic failure. Long-term follow-up and man-
agement of patients carrying HIV variants with
Fig. 2. Temporal evolution of circulating CD4 T-cell count (CD4 as black diamonds in cells ⁄ lL) and HIV-1 RNA viral load
(VL as open circles in log copies ⁄mL) for 11 patients whose HIV-1 variants contained peptide rearrangements in the RT pol
gene. Vertical lines represent the time of the ﬁrst discovery of insertion rearrangements.
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peptide rearrangements in codons 67–71 of the RT
pol gene showed clearly that such genetic change
is associated frequently with various patterns of
resistance mutations to antiretroviral drugs and
with sustained therapeutic failure. These obser-
vations raise the issue of peptide insertion rear-
rangements in the RT pol gene as a rare cause of
persistent therapeutic failure in patients treated
with antiretroviral drugs.
In our institution, rearrangement insertions in
the RT pol gene that conferred MDR were detec-
ted in plasma HIV-1 RNA from a minority (2.7%)
of patients in therapeutic failure. Similar low
prevalences have been reported previously in
hospital cohorts in which HIV-1 RT pol gene
rearrangements could be found in 0.7–2.7% of
multidrug-experienced patients for whom an HIV
genotypic resistance assay was carried out [5–
7,13,14].
In the present series, the most frequent dipep-
tide insertion was S–S (6 ⁄ 14); other dipeptide
insertions were A–S, A–V, S–C and S–Q. Mono-
peptide insertions were detected in < 10% of HIV
variants with RT pol gene rearrangements. Pep-
tide insertions were seen in HIV variants of both
A and B subtypes. The peptide insertions ap-
peared after variable treatment durations of not
less than 1 year, in agreement with a previous
report [4]. The insertions were observed only in
patients whose initial antiretroviral treatment was
either monotherapy or bitherapy with nucleoside
analogues. However, peptide insertions in the RT
pol gene have also been described in patients who
received triple therapy initially with ZDV plus
3TC plus indinavir [3]. Thus, peptide insertion
selection is not associated with a unique combi-
nation of antiretroviral drug classes or regimen.
The predominance of dipeptide over monopep-
tide insertions, and the patterns of peptide rear-
rangements in the RT pol gene, are similar to
series published previously [6]. The ﬁndings
further indicate that the amino-acid composition
pattern of insertions may vary with time in about
half of patients [4]. Peptide insertions were
always associated with various patterns of pre-
existing or appearing resistance mutations to
various antiretroviral drugs located in the RT pol
gene or in codons 67–71 ﬂanking the dipeptide
rearrangements, as also described previously [6].
As hypothesised previously [15], the variability
and instability of the insertion, and the ﬂanking
amino-acids, may be associated with a progres-
sive selection of variants with increased ﬁtness.
Taken together, these observations emphasise that
codons 67–71 constitute an unstable, highly plas-
tic region of the RT pol gene that is prone to
extensive genetic heterogeneity, giving rise to
peptide rearrangements, nucleotide substitutions
or resistance mutations.
Despite several antiretroviral shifts, most of the
patients in this study remained in virological and
immunological failure over 2–6 years. These ﬁnd-
ings indicate that the management of patients
carrying HIV variants with peptide insertions in
the RT pol gene remains challenging [6,7]. Dipep-
tide insertions in codon 69 have been found to be
associated with moderate to high levels of phen-
otypic resistance to several NRTIs, even in the
absence of mutations in the RT pol gene known to
confer resistance to these drugs, thereby demon-
strating that such rearrangements are effective
MDR inserts [6,7]. Furthermore, the numerous
associated resistance mutations and the insertion
are thought to act synergically to increase resist-
ance [4]. The extensive cross-resistance to NRTIs,
and the rapid selection of resistance to protease
inhibitors and NNRTIs when prescribed, as in the
patients described above, render the choice of
antiretroviral regimens extremely difﬁcult. The
proposed therapeutic options and genotypic-
guided treatment allowed effective virological
and immunological improvement in two patients
(6 and 9) despite cross-resistance to NRTIs. Both
patients had a long-term beneﬁcial response, with
an undetectable viral load and a progressive
increase in CD4 T-cell count, after the introduc-
tion of indinavir in patient 6, and of indinavir
followed successively by nelﬁnavir and an
NNRTI in patient 9. These patients received two
new antiretroviral drugs, including one protease
inhibitor shortly after the appearance of an
insertion. Patient 6 received d4T and indinavir
in addition to 3TC, and patient 9 received zalcit-
abine (ddC) and indinavir, followed 3 months
later by ddC and nelﬁnavir in addition to d4T.
Antiretroviral shifts consisted of only one drug
change in patients 3, 5, 8 and 10, while a protease
inhibitor already formed part of the antiretroviral
therapy in patients 1, 2, 7 and 11 before the
detection of amino-acid insertions. In contrast to
patients 6 and 9, most of the patients studied did
not respond, either virologically or immuno-
logically, to any of the various antiretroviral
regimens prescribed. All selected various patterns
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of resistance mutations to both NNRTIs and
protease inhibitors following their introduction,
and all developed AIDS-related conditions, lead-
ing to death in two patients. Salvage therapy in
patients harbouring HIV-1 variants with dipep-
tide insertions should preferably include two new
antiretroviral drugs, probably including a prote-
ase inhibitor, as in patients 6 and 9, but with no
guarantee of success.
In conclusion, the insertion of amino-acid(s) in
the ﬁngers subdomain of the HIV-1 RT pol gene
occurs rarely in patients in therapeutic failure, but
is associated with various patterns of cross-
resistance to most antiretroviral drugs. The
management of such patients is challenging, even
with repeated genetic determinations of the
resistance pattern of the circulating HIV variants.
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